Clinical Trial Update: Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients [Phase 1]

View source ↗

Summary

Phase 1 clinical trial of a dendritic cell/AML fusion cell vaccine given after allogeneic transplantation in acute myeloid leukemia patients is currently active…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Dendritic Cell/AML Fusion Cell Vaccine

Snippet

Sponsor: Beth Israel Deaconess Medical Center | Conditions: Acute Myelogenous Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING